Novo Nordisk has entered a strategic partnership with OpenAI to boost drug discovery and development, R&D World reports.
The collaboration will allow Novo Nordisk to analyse massive datasets at a scale previously not possible, with the aim of bringing new treatments to market faster.
The partnership spans research, manufacturing, supply chain and commercial operations, with pilot projects already underway and full integration planned by the end of 2026.
The move comes as Novo Nordisk is restructuring its business, cutting costs and slowing hiring, while facing growing competition in key markets such as China.
At the same time, the company is increasing its presence in China, where many new job openings are focused on sales roles for obesity and diabetes drugs.
The AI push builds on Novo Nordisk’s existing digital efforts, including internal AI tools and partnerships with major tech companies.
